Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959641 · ClinicalTrials.gov registry record · Phase 2
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
A Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Differentiated Thyroid Gland Carcinoma, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT06959641: Recruiting Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Differentiated Thyroid Gland Carcinoma, sponsored by Northwestern University.
NCT06959641 is a Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Differentiated Thyroid Gland Carcinoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06959641, a Phase 2 study of Metastatic Thyroid Gland Oncocytic Carcinoma and Locally Advanced Differentiated Thyroid Gland Carcinoma, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). XL092 is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing.
Primary Outcome
Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria. Median PFS at 12-months will be analyzed using the Kaplan-Meier method. The 12-month PFS estimate will be reported along with the confidence interval. Cox proportional hazards models will be applied to assess the impact of covariates such as age, sex, baseline disease severity, and genetic markers on PFS, when appropriate.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- OTHER Survey Administration
- PROCEDURE X-Ray Imaging
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2025-06-06 |
| Est. Completion | 2030-09-11 |
| Phase | Phase 2 |
What NCT06959641 shows while recruiting
NCT06959641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 10 conditions, with Metastatic Thyroid Gland Oncocytic Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06959641 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06959641 about?
NCT06959641 is a clinical study titled "XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer". This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where ...
What is the current status of trial NCT06959641?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2025-06-06. Estimated completion is 2030-09-11.
What conditions does trial NCT06959641 study?
This clinical trial studies the following conditions: Metastatic Thyroid Gland Oncocytic Carcinoma, Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma, Locally Advanced Thyroid Gland Oncocytic Carcinoma.
What interventions are being tested in trial NCT06959641?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Survey Administration (OTHER), X-Ray Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT06959641?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959641 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Thyroid Gland Oncocytic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06959641's enrollment target sits among peer trials
33 1553rd of 2000 higher than 439 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI